Fidelity Select Biotechnology Fund (FBIOX)
The Fidelity Select Biotechnology Fund aim is to seek capital appreciation. The mutual fund invests mainly in common stocks. It uses its assets to purchase securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes. It also invests in companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. |
| Fidelity fund details |
- Fund Inception Date: 12/15/1985
- Ticker Symbol: FBIOX
- CUSIP: 316390772
- Beta (3yr): 0.88
- Rank in category (YTD): 7%
- Category: Health
- Yield: 0.00%
- Capital Gains: 0%
- Expense Ratio: 0.83%
- Net Assets: $ 4.2 billion
- Number of Years Up: 21 years
- Number of Years Down: 6 years
- Annual Turnover Rate: 106%
Rajiv Kaul has managed this Fidelity fund since October 2005. It has $4.2 billion of total net assets. There is no dividend yield currently. The fund’s expense ratio is only 0.83%. There is no 12b1 fee for investing in this fund. There is also no front-end sales load fee. The average expense fee ratio in the Health category is 1.52%. The annual holdings turnover is rather high, 106.00%.
Sector Stock Fund
Morningstar analysts rank this health mutual fund with 5-stars rating. The YTD return as of April 10, 2013 is 20.17%. The fund has returned 31.78% over the past 1-year, 15.57% over the past 5-year and 12.88% over the past decade. Among the 21 years of positive return, the best 1-year total return was recorded in 1999. It was 77.77%. The worst was in 2002 with -40.53%. The 3-year beta risk is 0.88.Investors can buy this sector stock fund through their brokerage account. The minimum initial investment is $2,500 for regular brokerage and $500 for retirement (IRA) account. There is no minimum subsequent investment. The brokerages that provide the sale of this FBIOX fund are Raymond James, MSSB Retail Fund, Td Ameritrade Inc, E Trade Financial, JP Morgan, Royal Alliance, etc.
Fidelity Fund
The top 10 stocks in its holdings as of December 2012 are Gilead Sciences Inc, Amgen Inc, Biogen Idec Inc, Regeneron Pharmaceuticals Inc, Celgene Corp, Onyx Pharmaceuticals Inc, Medivation Inc, Alexion Pharmaceutical Inc, Biomarin Pharmaceutical Inc and Vertex Pharmaceutical Inc. These top ten represent 58.83% of the total portfolio (out of 151 holdings). The top asset allocation is Domestic Equities with 98.14%.More: 10 Great 401k Mutual Funds
According to the fund website, the principal investment risks are stock market volatility risk, foreign exposure risk, biotechnology industry concentration risk, issuer-specific changes risk, etc.
Disclosure: No Position
No comments:
Post a Comment